News

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...
Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...
Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.
We recently published a list of 10 Firms Crushing the Market. In this article, we are going to take a look at where Tempus AI ...
German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI (Nasdaq: TEM), ...
Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...
Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...
Live Updates Live Coverage Has Ended Tempus AI sentiment heading 3:43 pm by Tempus enters earnings with strong tailwinds but ...
Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...
Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...
Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...
We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...